Indication and timing of trough plasma-voriconazole (VCZ)-concentration (t-PVC) measurement during VCZ treatment is a debated issue. Patterns of t-PVC were prospectively evaluated in pediatric (50 courses) and adult (95 courses) hematologic patients. Efficacy patterns were defined: adequate, t-PVC always ≥1 mcg/ml; borderline, at least one t-PVC C The Author 2017. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
Introduction
Voriconazole (VCZ) is a broad-spectrum triazole antifungal agent with licensed indication in prophylaxis and therapy in adults and children aged 2 years and older. 1, 2 VCZ is metabolized via cytochrome P450 isoenzymes oxidative mechanisms. Metabolism may be influenced by genetic polymorphisms that have been associated with differing rates of enzyme activity, and by certain drugs able to inhibit or induce these isoenzymes. These factors justify the large inter-individual and intra-individual pharmacokinetic variability of VCZ with subsequent unpredictability of blood levels. 1, [3] [4] [5] [6] Reduced plasma levels have a potential impact on the systemic drug exposure with subsequent increased risk of treatment failure while high plasma levels are associated with greater probability of toxicity. 1, 7, 8 Because of the variability in VCZ metabolism, the measurement of the trough plasma VCZ concentration (t-PVC) (also defined therapeutic drug monitoring, TDM) has been recommended as a tool to optimize outcomes and reduce toxicity. [9] [10] [11] [12] However, there is no general consensus on the indication and timing of TDM during VCZ treatments considering that the definitive trials used for registration were all performed using a fixed regimen and large multicenter randomized controlled trials of TDM are currently not available to support definitive guidelines. Furthermore, in several countries only few centers have a clinical pharmacology laboratory able to measure plasma concentrations of triazoles. All these factors justify the inhomogeneous and noncodified practice of TDM in the clinical management of patients being treated with VCZ.
In this prospective, multicenter study we evaluated the inter-and intrapatient variability of t-PVCs in a "real life" scenario of adults and children with hematological diseases receiving non-TDM guided VCZ therapy or prophylaxis. The primary objective of the study was to identify the clinical conditions associated with predictable VCZ concentrations and define a tailored TDM strategy.
Methods

Study population and data collection
This prospective study was conducted from October 2012 through September 2013 among 14 hematologic centers in Rome, Florence, and Perugia (Italy). The study protocol was approved by the ethics committees of all centers. It was conducted in accordance with good clinical practice and the declaration of Helsinki. Written informed consent was obtained from each patient.
VCZ should have been administered according to the dosage indicated in the official fact sheet. 2 The licensed dose for adults was 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg IV twice daily (for oral treatment, 400 mg twice daily for two dosages, followed by 200 mg twice daily for body weight >40 kg and 200 mg twice daily for two dosages, followed by 100 mg twice daily for body weight <40 kg were recommended). For children (2 to <12 years) and young adolescents with low body weight (12 to 14 years and <50 kg) the recommended dose was 9 mg/kg IV twice daily for two dosages, followed by 8 mg/kg iv twice daily (for oral treatment a fixed 9 mg/kg twice daily is recommended). For all other adolescents Table 1 . Definitions of efficacy and toxicity t-PVC patterns * @ .
T-PVC efficacy patterns:
r Adequate: in this group were included courses in which t-PVC was always ≥1 mcg/ml. r Borderline: in this group were included courses in which at least one t-PVC measurement was <1 mcg/ml but the median value of the measurements was ≥1 mcg/ml.
r Inadequate: in this group were included courses in which the median value of the measurements was <1 mcg/ml.
T-PVC toxicity patterns:
r Favorable: in this group were included courses in which t-PVC was always ≤5 mcg/ml. r Borderline: in this group were included courses in which one or more t-PVC measurements were >5 mcg/ml but the median value of the measurements was ≤5 mcg/ml.
r Unfavorable: in this group were included courses in which the median value of the measurements was >5 mcg/ml.
t-PVC, trough plasma voriconazole concentration. * The calculated t-PVC patterns concerned the t-PVC measurements during the fixed regimen before any eventual TDM guided dose modification. The measurements performed after TDM guided VCZ dose modification were excluded from the analysis and the results described.
Various target concentrations associated with voriconazole efficacy have been reported. Most experts would aim for dosing to achieve a voriconazole trough of >1-1.5 μg/ml for efficacy but <5-6 μg/ml to minimize toxicity, primarily CNS toxicity. 15 We chose the more commonly used target concentration of 1 and 5 for efficacy and toxicity, respectively.
(12-14 years and >50 kg, and >14 years regardless of the body weight) VCZ should have been dosed as adults. No dosing regimen for prophylaxis was recommended being this indication off-label at the time of the study.
Investigators were asked to take the first blood sample after 5 days of VCZ therapy and thereafter every 7-10 days or based on clinical judgment in the suspect of treatment failure or drug-related side effects. Blood samples (4.5 ml) for determining t-PVCs were collected in EDTA or citrate tubes, were immediately centrifuged and separated plasma was stored at -80
• C. Samples were sent by courier to a central referral pharmacology laboratory (Department of Clinical Pharmacology, University of Florence) every 2-3 weeks. A validated high-pressure liquid chromatography assay was used to measure t-PVC. 13 The pharmacology laboratory communicated t-PVC results to each center within 1-2 weeks from samples receipt. Considering that investigators usually received the t-PVC results from the referral laboratory after several days from samples collection, the results could not be generally used for dose modification. This condition characterizes our study as a non-TDM guided VCZ treatments experience. Data were entered into electronic case report forms to collect demographic information, underlying disease and its treatment characteristics, VCZ dosing information, clinical data on adverse events, and efficacy of VCZ administered in therapy or prophylaxis.
Baseline or breakthrough invasive fungal diseases in patients receiving VCZ therapy and prophylaxis, respectively, were classified according to standard definitions. 14 
Inclusion criteria
Inpatients and outpatients with hematological diseases submitted to intensive chemotherapy, other immunosuppressive treatments or hematopoietic stem cell transplant (HSCT) were enrolled in this study. As each patient may have received multiple VCZ courses, the analysis was performed for each course. Multiple courses per each patient were considered if the drug administration was discontinued for at least 7 days of each other. Discontinuation of the drug for a shorter period was considered a temporary interruption during the same course and was reported in the case report form. Overall, only courses with one or more measurements after steady state (since day 5 of treatment) for treatments lasting less than 2 weeks and courses with at least two measurements for longer treatments were considered for the analysis. Courses lasting more than 2 weeks and with only one t-PVC measurement were excluded.
The calculated t-PVC patterns concerned the t-PVC measurements during the fixed regimen before any eventual TDM guided dose modification. The measurements performed after TDM guided VCZ dose modification were excluded from the analysis and the results described.
Analysis
The primary endpoints of the study were to describe the t-PVC efficacy and toxicity patterns (see definitions in Table 1) in a "real life" scenario of adults and children who received a non-TDM guided VCZ treatment at standard doses and to define conditions at different probability of out of range t-PVC. The secondary endpoints were the evaluation of a possible correlation between t-PVCs and treatment failure and side effects for each course. The data in children and adults were separately analyzed. Children population included patients aged <12 years and those aged 12 to 14 years with a weight <50 kg, adult population included patients aged >14 years and those aged 12-14 years with a weight ≥50 kg. These criteria were adopted considering the dosage recommendation according to age and body weight.
2
VCZ administration records for each patient were used to verify the time of t-PVC sampling. Samples erroneously collected out of the patient's dosing period were excluded.
Continuous data were presented as means (± standard deviations [SD]) or medians (ranges), and categorical data were expressed as numbers (proportions). T-test was used to compare the means of two groups. Univariate analyses were performed using the Fisher exact probability test to compare categorical variables. The independent impact of the variables possibly influencing the t-PVC patterns (adequate vs. borderline/inadequate for efficacy pattern and favorable vs. borderline/unfavorable for toxicity pattern) was assessed by binomial logistic regression analysis. All the probabilities we reported are two-sided. A P-value of <.05 was considered statistically significant. Statistical analysis was performed using SPSS v.17 (SPSS Inc., Chicago, IL).
Results
Overall, 163 VCZ courses in 158 patients were enrolled in the study, but 145 VCZ courses in 141 patients were considered (18 courses excluded from the analysis). Patients demographics and characteristics of the evaluable courses are described in Table 2 .
Pediatric population
Fifty VCZ courses in 50 children were considered for the analysis. The median duration of these courses was 30 days (range 5-224 days). Overall, 185 t-PVC measurements were performed over a period of 2250 cumulative days of VCZ administration. The overall mean t-PVCs was 2.3 mcg/ml ± 3.1 mcg/ml (range, <0.15 to 22.6). A t-PVC <1 mcg/ml, between 1 and 5 mcg/ml and >5 mcg/ml was detected in 82 (44.3%), 79 (42.7%), and 24 (13.0%) samples, respectively (Fig. 1A) .
VCZ was administered intravenously only, orally only, and sequentially intravenously-orally in 17, 13, and 20 courses, respectively. The mean daily dosage of VCZ during intravenous (13.6 mg/kg, range 5.4-20 mg/kg) and oral administrations (14.4 mg/kg, range 5-20 mg/kg) were comparable (P = .55). Overall, 108 and 77 t-PVC measurements were performed during intravenous and oral administrations, respectively. The mean t-PVCs were 2.8 mcg/ml (±3.7 mcg/ml) during intravenous therapy and 1.7 mcg/ml (±1.6 mcg/ml) during oral therapy (P = .02). In five patients the dosage of VCZ was modified in the light of t-PVC results: in two and three cases the dosage was decreased and increased, respectively, reaching in-range levels in all cases.
The t-PVC efficacy patterns were adequate in 24 courses (48.0%), borderline in six courses (12.0%) and inadequate in 20 courses (40.0%), being the cumulative median (range) t-PVC 2.54 (1-22.6), 1.36 (<0.15-6.5) and 0.69 (<0.15-11.12) mcg/ml, respectively. The correlation between the different t-PVC efficacy patterns (adequate vs borderline/inadequate) and patients clinical variables is detailed in Table 3 . Body weight above the median (>25 kg) was significantly more frequent in courses in which an adequate t-PVC pattern was documented (odds ratio 4.8 [95% CI 1.42-16.19]; P = .011).
The t-PVC toxicity patterns were favorable in 33 courses (66.0%), borderline in 13 courses (26.0%), and unfavorable in 4 courses (8.0%), being the cumulative median (range) t-PVC 1.0 (<0.15-4.9), 2.1 (<0.15-15.7), and 9.0 (5.3-22.6) mcg/ml, respectively. The correlation between the different t-PVC toxicity patterns (favorable vs. borderline/unfavorable) and patients clinical variables is detailed in Table 4 . VCZ dosage below the median (≤14 mg/kg) was significantly more frequent in courses with favorable t-PVC toxicity pattern (odds ratio 4.18 [95% CI 1.18-14.82]; P = .027).
In the pediatric population only one case of treatment failure was observed in a 4 year-old patient who received intravenous VCZ (daily dosage 15.2 mg/kg) for the treatment of a probable invasive aspergillosis and died after 17 days. The t-PVC efficacy pattern in this case was inadequate being all three t-PVC measurements under the therapeutic cut-off (0.8, 0.7, and 0.6 mcg/ml, respectively). No case of visual/neurological and two cases of increase of transaminases (CTC grade II) potentially related to the VCZ treatment during courses with borderline and unfavorable (one case each) t-PVC toxicity pattern, were reported.
Adult population
Ninety-five VCZ courses administered to 91 adults were considered for the analysis. The median duration of these courses was 42 days (range 5-280 days). Overall, 295 t-PVC measurements were available over a period of 4042 cumulative days of VCZ administration,. The overall mean of t-PVCs was 3.0 mg/L ± 2.7 mcg/ml (range, <0.15 to 16.1). A t-PVC <1 mcg/ml, between 1 and 5 mcg/ml and >5 mcg/ml was detected in 66 (22.4%), 179 (60.7%) and 50 (16.9%) samples, respectively (Fig. 1B) .
VCZ was administered intravenously only, orally only, and sequentially intravenously-orally in 26, 39, and 30 courses, respectively. The mean daily dosage of VCZ was 2 mg/kg) for oral administrations (P = .003). Overall, 137 and 158 t-PVC measurements were performed during intravenous and oral administration, respectively. The mean t-PVCs were 3.4 mcg/ml (±2.9 mcg/ml) during intravenous therapy and 2.6 mcg/ml (±2.5 mcg/ml) during oral therapy (P = .008). In three patients the dosage of VCZ was increased in light of low t-PVC, and adequate blood levels were documented in the following t-PVC measurements. The correlation between the different t-PVC efficacy patterns (adequate vs. borderline/inadequate) and patients clinical variables is detailed in Table 3 . At univariate analysis body weight above the median (>68 kg) and an active hematological disease were significantly more frequent in courses with an adequate t-PVC pattern. At binomial logistic regression analysis, an active hematological disease maintained a statistically significant association with adequate t-PVC efficacy pattern (odds ratio 3.93 [95% CI 1.48-10.39]; P = .006).
The t-PVC toxicity patterns were favorable in 70 courses (73.7%), borderline in 8 courses (8.4%), and unfavorable in 17 courses (17.9%), being the cumulative median (range) t-PVC 1.75 (<0.15-4.9), 3.95 (0.38-10.3), and 7.2 (5.2-16.1) mcg/ml, respectively. The correlation between the different t-PVC toxicity patterns (favorable vs. borderline/unfavorable) and patients clinical variables is detailed in Table 4 . Body weight over the median (≥68 kg) was significantly associated with borderline/unfavorable t-PVC toxicity pattern (odds ratio 0.22 [95% CI 0.079-0.63]; P = .004).
In the adult population, three cases of treatment failure were observed in patient with probable invasive aspergillosis: the first patient developed a breakthrough pulmonary zygomycosis (t-PVC in two samples was 0.93 and 1.55 mcg/ml); the second patient developed a VCZ susceptible C.albicans breakthrough septicemia coinciding with the decrease of t-PVC (t-PVC in three samples was 1.4, 1.6, and 0.24 mcg/ml); the third patient was persistently febrile after 8 days of VCZ therapy and improved after changing to liposomal amphotericin B (t-PVC in two samples was 0.43 and 0.55 mcg/ml). With regard to toxicity, five cases of visual/neurological side effects (hallucinations in three cases psychosis in two cases) and two cases of significant increase of transaminases (CTC grade II), all during courses with unfavorable t-PVC toxicity pattern, were reported.
Discussion
There is wide evidence that the t-PVC range of 1 to 5-6 mcg/ml is the therapeutic target for a clinically appropriate efficacy-safety profile during VCZ treatment. 9 TDM has been recommended for a proper use of the drug and CYP2C19 genotyping has been suggested to guide VCZ initial dosing. [3] [4] [5] However, there are no validated algorithms on t-PVC monitoring and CYP2C19 genotyping. While CYP2C19 genotype data may explain variability of VCZ serum levels, they alone are not sufficient to guide initial dosing and the availability of pharmacogenomic testing in treatment of individual patients also remains challenging in real life. 4 The majority of studies exploring the impact of VCZ TDM on efficacy and safety have found TDM to be beneficial. 7, 16 On the other hand, whether to use the t-PVC monitoring in all patients receiving VCZ and throughout the entire treatment or only in selected patients and treatment phases is a debated issue for several factors, including the fact that TDM is potentially expensive and time consuming and that in certain countries only a minority of hospitals have a clinical pharmacology laboratory that is able to dose the level of antifungal drugs. Probably because of all these reasons, TDM during VCZ treatment still does not represent a routine practice in several hospitals. In our experience, actually only two of 14 centers have the opportunity to take the exam inside of their hospital and the others only occasionally send blood samples for this analysis outside. An alternative to a universal TDM schedule may be an approach based on the identification of clinical scenarios where the risk of pharmacokinetic unpredictability is high. Conversely, in subpopulations at low risk of subtherapeutic VCZ levels a non-TDM guided treatment strategy may be justified.
The main results of the published studies in which the factors possibly associated with t-PVC variability in pediatric and adult populations were analyzed are summarized in Table 5 . [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The results of these studies may be difficult to compare each other and with our experience considering the different parameters used in the analysis of the data. There was a variability in describing the t-PVC patterns and in the factors considered for a possible correlation with t-PVC. The median t-PVC ranged from 0.9 to 3.0 mg/l, subtherapeutic levels (<0.5 or <1 mg/l) ranged from 18% to 58% of samples and levels over the therapeutic target considered (>2, >4, >5, or >5.5 mg/l) ranged from 2% to 30.6% of samples. The rate of samples into the therapeutic target ranged from 34% to 71.3% of samples. In our study, the median t-PVC was 2.3 mg/l in children and 3.0 mg/l in adults. T-PVC <1, 1 to 5, and >5 mg/l were observed in 44.3%, 42.7%, and 13% of samples, respectively, in children, and in 22.4%, 60.7%, and 16.9% of samples, respectively, in adults. Almost all the published TDM experiences reported the data on t-PVC as the median or mean of measurements at initial dosing or of all measurements during the treatment courses. This way of reporting the data might not take into account the intrapatient variability of the t-PVC. For example, in a VCZ treatment course with multiple tPVCs over the target and a single measurement under the target the median t-PVC is satisfactory, but during a certain period, the patient may not be protected from infection due to a transitory subtherapeutic blood level of the drug. In our experience we analyzed the data considering t-PVC efficacy and toxicity patterns that describe the t-PVC adequacy over time, although, due to the limited number of samples collected in some patients, the data may not be always representative of the whole treatment period.
Literature data and our experience show important differences in the VCZ pharmacokinetic between children and adults. With the limit of a difficult comparability of the studies, subtherapeutic levels were more frequent in children, while there was no relevant difference in the supratherapeutic t-PVC levels rate between children and adults.
Pharmacokinetic studies in children demonstrated that the VCZ dose required to achieve therapeutic concentrations is age dependent. In a retrospective study in 44 immunocompromised children who received VCZ and underwent TDM at steady state, at least one therapeutic level was achieved in only 52.3% of courses. 20 Patients aged <6, 6-12, and >12 years required median intravenous doses of 8.8, 7.5, and 4.0 mg/kg twice daily, respectively. However, the high doses suggested for children do not always guarantee therapeutic levels particularly in younger patients. In a retrospective study in children submitted to HSCT only 14% of <2 years patients versus 32% of 2-12 years and 50% of >12 years reached a VCZ adequate level at initial dosing. 19 In order to reach adequate t-PVCs, doses were increased in 57% of patients, and the median daily dose to reach an adequate t-PVC in children of <2 years, 2 to 12 years, and above 12 years of age was 31.5 mg/kg (range 12 to 70 mg/kg), 16 mg/kg (range 13 to 55 mg/kg), and 9.4 mg/kg (range 7.5 to 20 mg/kg), respectively. No factor, other than age, was associated with the t-PVC interpatient and intrapatient variability in pediatric series. [17] [18] [19] [20] In our study, while confirming a lower probability of adequate t-PVC efficacy pattern in younger children, we observed a significant impact of the body weight: the probability of an adequate pattern was more frequent in children weighting ≥25 kg (64% of courses) as compared to those weighting ≤25 kg (27% of courses) (P = .012). Contrary to other studies, we observed a significantly higher mean t-PVC in samples taken during intravenous administration as compared to oral treatments. With regard to the t-PVC toxicity patterns in children, lower VCZ doses were significantly associated to an increased rate of favorable patterns, but only 8% of patients experienced an unfavorable toxicity pattern.
In adults, no correlation between weight-adjusted VCZ dosage and t-PVC was found in our experience and in most of published studies. [21] [22] [23] [24] 26, 29 No significant difference of t-PVC was observed in most studies between intravenous and oral VCZ treatments. 24, 25, 27, 29 In our study we found higher mean t-PVCs during intravenous administration, but this may be, at least partially, due to the higher per kg doses used for intravenous treatments. No correlation was found between VCZ levels and baseline differences in age, sex, duration of neutropenia, presence of GVHD, use of combined antifungals, duration of VCZ treatment, gastrointestinal tract abnormality, administration via nasogastric tube, serum creatinine and liver enzymes. 24, 26, 28, 29 In our experience, weighting more than 68 kg and active hematological disease were significantly associated to a higher rate of adequate t-PVC efficacy pattern at univariate analysis, while only phase of hematological disease remained significant at binomial logistic regression analysis. This finding may be explained by the fact that VCZ levels were higher during intravenous treatments and VCZ was generally administered intravenously in hospitalized patients with active hematological disease (i.e., at onset or resistant/relapsed leukemia).
As for the t-PVC toxicity patterns in the adult population only higher body weight was significantly associated to an increased rate of borderline/unfavorable patterns. In both children and adults the body weight had a certain impact in the VCZ pharmacokinetic with increasing levels in heavier patients. This datum is in agreement with a study in which patients with higher body mass index tended to have significantly higher median random VCZ concentrations particularly during intravenous administration. 31 Although our study was not designed for evaluating the relationship between the t-PVCs and the outcome of the treatments, it confirms the correlation between the VCZ blood levels and its efficacy and toxicity profile. Indeed, we observed that the few cases of treatment failure occurred in patients with inadequate t-PVC efficacy pattern and the cases of neurological, visual, and hepatic toxicity occurred in patients with borderline/unfavorable t-PVC toxicity pattern.
In conclusion, our study confirms the significant interpatient and intrapatient variability of VCZ blood levels both in pediatric and adult patients with hematological diseases. In children the risk of inappropriate t-PVCs is very high in low-body weight younger patients but also in adolescents there is a significant and unpredictable rate of subtherapeutic blood levels. Indeed, we did not identify a pediatric subpopulation in which a non-TDM guided VCZ treatment strategy may be safely considered. Even in adults the risk of out of range t-PVCs is relevant but a non-TDM guided No IFD was documented. No significant side effects were observed in two children whose t-PVC were above the target range (>5 mg/ml).
Pieper et al. 2012 18 Retrospective, therapy and prophylaxis; mainly hematological diseases (101; 251) The median t-PVC was 1.4 mg/l. Trough levels
≤1, >1
-<5, and ≥5 mg/l were observed in 58%, 34% and 8% of samples, respectively.
No evaluation of CYP450 polymorphisms in this study. No significant relationships between daily dose and t-PVC were observed. There was a weak correlation between orally administered absolute doses and the t-PVC. There was no significant correlation between dose and t-PVC for children aged 2-6 or 7-12 years; for children ≤24 months and adolescents >12 years, there was a weak relationship between dose and t-PVC.
There were no consistent correlations between dose, t-PVC and laboratory/clinical adverse events or treatment response, and proposed threshold values were not discriminative.
Bartelink et al. 2013 19
Retrospective, therapy and prophylaxis; HSCT (61; 380) 34% of pts reached an adequate level at initial dosing:
14, 32, and 50% in the three age groups of <2, 2 to 12, and 12 to 20 years, respectively (P = .354). 61% of patients had a subtherapeutic t-PVC, of which 56% had a t-PVC below the limit of detection (<0.5 mg/l), whereas 5% had an initial t-PVC of >5 mg/l. In
80% of patients an adequate t-PVC was reached after TDM-based dose adjustments
No evaluation of CYP450 polymorphisms in this study. Interpatient variability was high and was only partly related to age and/or body weight. Route of VCZ administration did not significantly influence t-PVC: after intravenous administration, 38% reached an adequate level initially versus 43% after oral administration (P = .800).
VCZ was discontinued in 6 patients due to toxicity. These patients had a median t-PVC of 0.5 mg/l at the initial dose (ranging from 0.5 to 2.6 mg/l), and a medium maximal concentration of 4 mg/l was reached after dose adjustment. μg/ml; P = .046).
There was no significant association between age, sex, and PPI use and t-PVC VCZ concentrations were correlated with higher serum alkaline phosphatase, bilirubin and aspartate aminotransferase levels, but not with other liver enzyme levels.
GautierVeyret et al. 2015 29 Retrospective, therapy; HSCT (33;
308) The median t-PVC was 1.3 mg/l. T-PVC ≤1, >1 -
≤5,
and >5 mg/l were observed in 40%, 58% and 2% of samples, respectively and 85%
of patients had at least one inadequate t-PVC during their course of treatment.
Cytochrome P450 genetic polymorphisms (combined genetic scores according to CYP2C19 and CYP3A genotypes) significantly affected the t-PVC. VRC IV administration was associated with a higher initial t-PVC compared to oral treatment (IV, 1.7 mg/l, versus oral, 1.0 mg/l (P = .03).
Sex, age, body mass index, and enzymatic inhibitor treatment as well as transaminase levels had no impact on t-PVC. Use of PPIs, in particular esomeprazole, was associated with increased t-PVC. Immunosuppressive therapies, including calcineurin inhibitors, mycophenolate, or everolimus, had no effect on subsequent t-PVC. T-PVC was not influenced by comedication with various CYP2C19 and/or CYP3A enzyme inhibitors. T-PVC was not influenced by diarrhea during oral treatment.
No evaluation of efficacy and toxicity correlations with t-PVC in this study.
Cojutti et al. 2016 30 Retrospective, No evaluation of efficacy and toxicity correlations with t-PVC in this study.
AML, acute myeloid leukemia; GVHD, graft versus host disease; HSCT, hematopoietic stem cell transplant; MDS, myelodisplastic syndrome; PPI, proton pump inhibitor; TDM, therapeutic drug monitoring; t-PVC, trough plasma voriconazole concentration; VCZ, voriconazole.
strategy may be considered in higher body weight patients receiving intravenous therapy. Considering the low rate of supratherapeutic levels and related side effects, particularly in children, the risk of supratherapeutic t-PVCs does not represent an important indication for TDM. This study has a number of limitations, including the non-homogeneous methodology of blood sampling. However, we were able to evaluate in a large, prospective, reallife scenario the rate of inappropriateness, in term of both sub-therapeutic and supra-therapeutic blood levels, of non-TDM guided VCZ treatments in high risk pediatric and adult patients. These data may be of help in the drive to a targeted use of TDM during VCZ treatments.
